Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q13896859> ?p ?o }
Showing triples 1 to 33 of
33
with 100 triples per page.
- Q13896859 subject Q6809004.
- Q13896859 subject Q8431759.
- Q13896859 subject Q8805811.
- Q13896859 abstract "Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda) is a humanized antibody used in cancer immunotherapy. It targets the programmed cell death 1 (PD-1) receptor. The drug was initially used in treating metastatic melanoma.Pembrolizumab was invented by Gregory Carven, Hans van Eenennaam and John Dulos at Organon Biosciences which later became Schering Plough Research Institute and then Merck & Co. MRC Technology humanized the antibody pembrolizumab for Organon in 2016.On September 4, 2014 the US Food and Drug Administration (FDA) approved pembrolizumab under the FDA Fast Track Development Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation. It is marketed by Merck.On October 2, 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer in patients whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents.".
- Q13896859 wikiPageExternalLink keytruda_pi.pdf.
- Q13896859 wikiPageExternalLink www.keytruda.com.
- Q13896859 wikiPageWikiLink Q17163357.
- Q13896859 wikiPageWikiLink Q17853226.
- Q13896859 wikiPageWikiLink Q18030399.
- Q13896859 wikiPageWikiLink Q18039630.
- Q13896859 wikiPageWikiLink Q180614.
- Q13896859 wikiPageWikiLink Q181876.
- Q13896859 wikiPageWikiLink Q2012719.
- Q13896859 wikiPageWikiLink Q204711.
- Q13896859 wikiPageWikiLink Q2459042.
- Q13896859 wikiPageWikiLink Q247489.
- Q13896859 wikiPageWikiLink Q3658562.
- Q13896859 wikiPageWikiLink Q5425270.
- Q13896859 wikiPageWikiLink Q5939625.
- Q13896859 wikiPageWikiLink Q640448.
- Q13896859 wikiPageWikiLink Q6809004.
- Q13896859 wikiPageWikiLink Q79460.
- Q13896859 wikiPageWikiLink Q8084905.
- Q13896859 wikiPageWikiLink Q8431759.
- Q13896859 wikiPageWikiLink Q8805811.
- Q13896859 wikiPageWikiLink Q974135.
- Q13896859 type ChemicalSubstance.
- Q13896859 type Drug.
- Q13896859 type ChemicalObject.
- Q13896859 type Thing.
- Q13896859 type Q8386.
- Q13896859 comment "Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda) is a humanized antibody used in cancer immunotherapy. It targets the programmed cell death 1 (PD-1) receptor. The drug was initially used in treating metastatic melanoma.Pembrolizumab was invented by Gregory Carven, Hans van Eenennaam and John Dulos at Organon Biosciences which later became Schering Plough Research Institute and then Merck & Co.".
- Q13896859 label "Pembrolizumab".